相关实验视频
Updated: Sep 12, 2025

03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
531
PPDPF通过c-Myc/CD24轴促进食道状细胞癌的进展
Bing Zhu1,2, Ning Ma3, Zhi-Chao Liu3
1Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
Journal for immunotherapy of cancer
|August 7, 2025
概括
胰腺原始细胞分化和增殖因子 (PPDPF) 通过稳定c-Myc和增加CD24促进食道状细胞癌 (ESCC),导致免疫逃逸. 针对PPDPF或CD24为ESCC提供了一个新的免疫治疗策略.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 免疫治疗是一种免疫疗法.
背景情况:
- 尽管免疫疗法取得了进展,食道状细胞癌 (ESCC) 的预后不佳.
- 目前针对ESCC的免疫治疗方法的疗效有限.
- 需要新的治疗目标来改善ESCC的治疗结果.
研究的目的:
- 确定ESCC的新型免疫疗法点.
- 研究胰腺原生细胞分化和增殖因子 (PPDPF) 在ESCC进展中的作用.
- 阐明PPDPF促进ESCC瘤生长和免疫逃避的机制.
主要方法:
- 利用ESCC细胞系和小鼠模型研究PPDPF功能和CD24阻塞.
- 进行RNA测序,分析PPDPF缺陷时的转录组变化.
- 采用了细胞化试验,免疫阻塞和共同免疫沉来研究分子机制.
- 分析临床ESCC样本进行验证.
主要成果:
- 在ESCC中,PPDPF的表达显著上调,并促进小鼠的瘤发育.
- PPDPF通过干扰c-Myc-GSK3β相互作用来增强c-Myc的稳定性,从而增加CD24表达.
- 增加CD24表达促进免疫系统从巨细胞灭菌中逃脱.
- 在临床样本中发现了PPDPF,c-Myc和CD24之间的正相关性.
- 在临床前模型中,抗CD24疗法有效抑制了ESCC瘤的生长.
结论:
- 在ESCC中,PPDPF通过调节c-Myc/CD24轴作为瘤蛋白起作用.
- PPDPF/c-Myc/CD24通路代表了ESCC免疫疗法的潜在治疗标.
- 向CD24在临床前ESCC模型中显示出有效性,表明其作为免疫治疗策略的潜力.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Mitogens and the Cell Cycle
6.8K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.8K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
MAPK Signaling Cascades
6.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.1K

